Literature DB >> 22659183

HSC90 is required for nascent hepatitis C virus core protein stability in yeast cells.

Naoko Kubota1, Yasutaka Inayoshi, Naoko Satoh, Takashi Fukuda, Kenta Iwai, Hiroshi Tomoda, Michinori Kohara, Kazuhiro Kataoka, Akira Shimamoto, Yasuhiro Furuichi, Akio Nomoto, Akira Naganuma, Shusuke Kuge.   

Abstract

Hepatitis C virus core protein (Core) contributes to HCV pathogenicity. Here, we demonstrate that Core impairs growth in budding yeast. We identify HSP90 inhibitors as compounds that reduce intracellular Core protein level and restore yeast growth. Our results suggest that HSC90 (Hsc82) may function in the protection of the nascent Core polypeptide against degradation in yeast and the C-terminal region of Core corresponding to the organelle-interaction domain was responsible for Hsc82-dependent stability. The yeast system may be utilized to select compounds that can direct the C-terminal region to reduce the stability of Core protein.
Copyright © 2012 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22659183     DOI: 10.1016/j.febslet.2012.05.023

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  3 in total

Review 1.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

Review 2.  Contribution of yeast models to virus research.

Authors:  R Sahaya Glingston; Jyoti Yadav; Jitika Rajpoot; Neha Joshi; Shirisha Nagotu
Journal:  Appl Microbiol Biotechnol       Date:  2021-06-04       Impact factor: 4.813

3.  The Phospholipid:Diacylglycerol Acyltransferase Lro1 Is Responsible for Hepatitis C Virus Core-Induced Lipid Droplet Formation in a Yeast Model System.

Authors:  Shingo Iwasa; Naoko Sato; Chao-Wen Wang; Yun-Hsin Cheng; Hayato Irokawa; Gi-Wook Hwang; Akira Naganuma; Shusuke Kuge
Journal:  PLoS One       Date:  2016-07-26       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.